019170.KS
Shinpoong Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 10,100.00
−2.70%Year over year
Reported trailing growth
- Revenue
- +6.2%
- EBITDA
- -71.7%
- EBIT
- +128.1%
- EPS
- +95.5%
- Free cash flow
- +245.1%
- Operating cash flow
- +480.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.9%
- EBITDA
- —
- EBIT
- +169.7%
- Net income
- +157.4%
- EPS
- +157.3%
- Free cash flow
- +164.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026